Kenneth Hoberman
2017
In 2017, Kenneth Hoberman earned a total compensation of $1.9M as Chief Operating Officer at Stemline Therapeutics, a 44% decrease compared to previous year.
Compensation breakdown
| Bonus | $243,918 |
|---|---|
| Non-Equity Incentive Plan | $28,070 |
| Salary | $443,487 |
| Stock Awards | $1,156,927 |
| Total | $1,872,402 |
Hoberman received $1.2M in stock awards, accounting for 62% of the total pay in 2017.
Hoberman also received $243.9K in bonus, $28.1K in non-equity incentive plan and $443.5K in salary.
Rankings
In 2017, Kenneth Hoberman's compensation ranked 5,821st out of 14,666 executives tracked by ExecPay. In other words, Hoberman earned more than 60.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,821 out of 14,666 | 60th |
Division Manufacturing | 2,117 out of 5,772 | 63rd |
Major group Chemicals And Allied Products | 660 out of 2,075 | 68th |
Industry group Drugs | 509 out of 1,731 | 71st |
Industry Pharmaceutical Preparations | 404 out of 1,333 | 70th |
Source: SEC filing on April 30, 2018.
Hoberman's colleagues
We found two more compensation records of executives who worked with Kenneth Hoberman at Stemline Therapeutics in 2017.